-
Advancing Understanding of Castleman Disease in China: A Multicenter Retrospective Study
Introduction: Castleman disease (CD) is a rare lymphoproliferative disorder characterized by heterogeneous clinical manifestations and outcomes. Despite its rarity, CD poses significant diagnostic and therapeutic challenges due to its diverse…
-
Advancements and Disparities in Autologous Hematopoietic Stem Cell Transplantation for Lymphoma and Multiple Myeloma: Insights from China
Abstract: This retrospective study aimed to delineate the utilization trends of autologous hematopoietic stem cell transplantation (AHSCT) for lymphoma and multiple myeloma (MM) in China, utilizing data from 211 AHSCT…
-
APASL Lecture Hall | Prof. Jun Li: Latest Developments in ACLF Early Warning Models, Leading the Way with Large Sample Data from China
ACLF, with its complex triggers and unclear pathogenesis, exhibits high mortality rates under internal medicine comprehensive treatment. In European and American populations, alcoholic liver cirrhosis predominates (60.3%), with severe bacterial…
-
Refractory patients with favorable/intermediate-risk acute myeloid leukemia benefit from azacytidine maintenance therapy following allogeneic hematopoietic stem cell transplantation
In September 2023, a study led by professor Erlie Jiang from Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science published in Hematological Oncology, focused on the effectiveness of azacytidine (AZA) maintenance therapy post-allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with acute myeloid leukemia (AML). Through propensity score matching, the research…
-
The Composite Immune Risk Score predicts overall survivalafter allogeneichematopoietic stem cell transplantation: A retrospective analysis of 1838 cases
In November 2022, professor Erlie Jiang and his team from Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science published a crucial study in the American Journal of Hematology, focusing on the impact of the Composite Immune Risk Score on survival after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Analyzing 1838 cases, the…
-
Refractory cytomegalovirus infections in Chinese patients receiving allogeneic hematopoietic cell transplantation: a review of the literature
In December 2023, professor Erlie Jiang and team from Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science published an influential study in Frontiers in Immunology, detailing the challenges of managing refractory cytomegalovirus (CMV) infections in Chinese patients after allogeneic hematopoietic cell transplantation (allo-HCT). With a focus on China’s unique position in…
-
Outcomes of acute myeloid leukemia patients undergoing allogeneichematopoietic stem cell transplantation: validation, comparison and improvement of 2022 ELN genetic risk system
In February 2024, professor Erlie Jiang and colleagues from Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science published a pivotal study in Experimental Hematology & Oncology , focusing on the validation and enhancement of the 2022 European LeukemiaNet (ELN) genetic risk system for acute myeloid leukemia (AML) patients undergoing allogeneic hematopoietic…
-
Comparison of autologous,matched sibling,andalternative donor stem cell transplant outcomes for acute myeloid leukemia patients in first remission: A propensity score matching study
In September 2023, a pivotal study led by professor Erlie Jiang from Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science was published in Hematology, focusing on acute myeloid leukemia (AML) patients in their first remission and comparing outcomes between autologous, matched sibling, and alternative donor stem cell transplants. This research innovatively…
Connecting Medical Expertise through Media